Multicenter validation study of a transplantation-specific cytogenetics grouping scheme for patients with myelodysplastic syndromes
about
Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation.Hematopoietic stem cell transplantation for MDS.Outcome of allo-SCT for women with MDS or AML occurring after breast cancer therapyImpact of the International Prognostic Scoring System cytogenetic risk groups on the outcome of patients with primary myelodysplastic syndromes undergoing allogeneic stem cell transplantation from human leukocyte antigen-identical siblings: a retrosRole and timing of hematopoietic cell transplantation for myelodysplastic syndrome.Impact of the revised International Prognostic Scoring System, cytogenetics and monosomal karyotype on outcome after allogeneic stem cell transplantation for myelodysplastic syndromes and secondary acute myeloid leukemia evolving from myelodysplastiClassifying cytogenetics in patients with acute myelogenous leukemia in complete remission undergoing allogeneic transplantation: a Center for International Blood and Marrow Transplant Research studyDoes iron overload really matter in stem cell transplantation?Current status of allogeneic hematopoietic cell transplantation for MDS.A disease risk index for patients undergoing allogeneic stem cell transplantation.Five-group cytogenetic risk classification, monosomal karyotype, and outcome after hematopoietic cell transplantation for MDS or acute leukemia evolving from MDS.Monosomal karyotype at the time of diagnosis or transplantation predicts outcomes of allogeneic hematopoietic cell transplantation in myelodysplastic syndrome.Allogeneic hematopoietic cell transplantation for myelodysplastic syndrome: the past decade.Mutational analysis of therapy-related myelodysplastic syndromes and acute myelogenous leukemia.Outcome and prognostic factors for patients who relapse after allogeneic hematopoietic stem cell transplantation.Allogeneic hematopoietic cell transplantation for myelodysplastic syndrome: current status.Up-to-date tools for risk assessment before allogeneic hematopoietic cell transplantation.Allogeneic hematopoietic stem cell transplantation in adults with myelodysplastic syndrome: Experience of the Argentinean Group of Bone Marrow Transplantation (GATMO).Long-term outcome of HLA-haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion based on an FBCA conditioning regimen for hematologic malignancies.Monosomal karyotype predicts poor survival after allogeneic stem cell transplantation in chromosome 7 abnormal myelodysplastic syndrome and secondary acute myeloid leukemia.Evaluation of a disease risk index for adult patients undergoing umbilical cord blood transplantation for haematological malignancies.Allogeneic Hematopoietic Stem Cell Transplantation In Therapy-Related Myeloid Neoplasms (t-MN) of the Adult: Monocentric Observational Study and Review of the Literature.Outcome of hematopoietic stem cell transplantation is similar for patients with a partial in vitro T-cell-depleted graft compared with a non-T-cell-depleted graft when stratified by the refined disease risk index.Specific abnormalities versus number of abnormalities and cytogenetic scoring systems for outcome prediction after allogeneic hematopoietic SCT for myelodysplastic syndromes.
P2860
Q33718837-5872B345-6483-411A-9DF5-24165FB803C9Q33767314-300BA5EF-48F4-4DBC-92EC-F9A1E9161774Q33928011-E8A49BA0-F68F-41F7-BF84-FF32F0D3CE68Q34272525-E2F8E5C8-69EC-4B1A-A82C-58673641A744Q34549306-3875D2A8-2C0D-45C7-AFD7-B085D142EB0BQ35146316-DF8845B7-152E-42DB-94C1-9A80D647B1A3Q35574597-D2DDBF43-540B-4E79-8EAD-273E4CD76DD0Q35981569-37D7A560-86F1-4035-8154-521662592DCCQ36063049-842E46DD-83BE-4614-AFF9-C3B09F38EFECQ36141944-C35CB3AB-D05F-4205-BC2C-C16CAF136695Q36339459-AFFB4EE3-BA75-41CA-BC51-57C531A98B5CQ36683757-F9916AC1-9A61-400B-8317-0589B7E4259CQ36811828-E7C21964-BE06-483C-BFBD-490CEDC52AF1Q36892587-4954F26F-E75F-41A8-8C10-B35FB70381C4Q37359736-E7605E2E-51F3-4DDB-9637-A96B35D6EA22Q37964938-0615EE51-3CFF-4B47-8A7F-3E0BD15D7174Q38858092-6B760ABF-CBBC-4A1C-B88F-C06348EA532EQ40766061-2FE346C9-6645-4B7C-A2BB-7223E8EDD4F0Q41747328-1B42297B-FE7F-4CCF-95C2-92AB1E5864EEQ43451303-C46E4C82-58FA-4C81-9828-92CBB5B8F1D6Q48162997-4FC080E1-D177-436C-AD23-45FD59E982ADQ49233865-F906FADD-BBE3-4208-8E34-5006E703C395Q52881816-A038A8EF-F792-4EC7-8ECE-A1B1A0CE972EQ53090413-CD4DF14F-F7A8-454E-8D35-A5851EF8F6E1
P2860
Multicenter validation study of a transplantation-specific cytogenetics grouping scheme for patients with myelodysplastic syndromes
description
2009 nî lūn-bûn
@nan
2009 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Multicenter validation study o ...... with myelodysplastic syndromes
@ast
Multicenter validation study o ...... with myelodysplastic syndromes
@en
type
label
Multicenter validation study o ...... with myelodysplastic syndromes
@ast
Multicenter validation study o ...... with myelodysplastic syndromes
@en
prefLabel
Multicenter validation study o ...... with myelodysplastic syndromes
@ast
Multicenter validation study o ...... with myelodysplastic syndromes
@en
P2093
P2860
P356
P1476
Multicenter validation study o ...... with myelodysplastic syndromes
@en
P2093
P Armistead
R J Soiffer
P2860
P2888
P304
P356
10.1038/BMT.2009.253
P407
P577
2009-09-28T00:00:00Z
P5875
P6179
1044963737